Upping the Ante for Predicting the Success of Alzheimer Disease Treatments
By Hugo Geerts, PhD, Piet van der Graaf, PharmD, PhD Over the past 20 years,…
CertaraFebruary 8, 2024
Drug Development’s New Model: Biosimulation from Discovery to Label Expansion
Key Highlights: How predictive technologies reshape drug development, mitigating project risks, navigating novel biomarkers, predicting…
CertaraFebruary 2, 2024
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader…
CertaraFebruary 1, 2024
Pharmacokinetic – toxicodynamic Modeling to Elucidate the Involvement of Dorsal Root Ganglion Neuron in Oxaliplatin – induced Peripheral Neurpathu
See how DRG‑based PK‑TD modelling predicts neuropathy severity and supports safer oxaliplatin dosing strategies using…
CertaraFebruary 1, 2024
Chemical data migration best practices – Stage 3: Data migration
Navigate the complexities of chemical data migration, from planning to production. Explore timelines, ETL methods,…
CertaraJanuary 30, 2024
Comparative simulation of intraperitoneal aminoglycoside regimens for patients with peritonitis on automated peritoneal dialysis
Learn how both regimens achieve PK/PD targets; fixed‑dose regimen recommended with trough monitoring, modelled using…
CertaraJanuary 30, 2024
Navigating the “Patent Cliff”: Omni-channel Strategies for Loss of Exclusivity and Established Products
Join us to understand the dynamics of the pharmaceutical market and learn how to maintain…
CertaraJanuary 24, 2024
